Trial Profile
Crossover evaluation of anagliptin versus sitagliptin on blood glucose levels using continuous glucose monitoring system in insulin-treated type 2 diabetes.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Nov 2018
Price :
$35
*
At a glance
- Drugs Anagliptin (Primary) ; Sitagliptin (Primary)
- Indications Diabetes mellitus
- Focus Therapeutic Use
- 12 Nov 2018 Status changed from recruiting to discontinued.
- 22 Apr 2017 Status changed from not yet recruiting to recruiting.
- 25 Oct 2016 New trial record